Product Highlight - ROSUZET
03 Mar 2023
•Powerful reduction in LDL-C1
•Rosuvastatin/ Ezetimibe fixed-dose combination provided significantly greater reduction in LDL-C level by 59%-63%1
Selected safety information (SSI)2: Contraindications: Hypersensitivity. Patients w/ active liver disease.
Pregnancy & lactation. Women of child-bearing potential not using appropriate contraceptive measures. Precautions: Discontinue therapy if CK levels are markedly elevated (>10 x ULN) or if myopathy is diagnosed or suspected. Patients w/ predisposing factors for myopathy. Temporarily w/ held therapy in patients w/ an acute serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis. Concomitant use w/ ciclosporin, fibric acid derivatives (including gemfibrozil), nicotinic acid, azole antifungals & macrolides; daptomycin; gemfibrozil; fenofibrate & other fibrates; anticoagulant. Diabetes mellitus. Patients who consume excessive quantities of alcohol &/or have a history of liver disease. Not recommended in patients w/ moderate or severe hepatic impairment. Asians. Adverse events: Common: Pruritus
References:
1. Kim KJ, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovas Ther. 2016 Oct;34(5):371-82.
2. Full product information of Rosuzet: S-CDDS-MK0653H-T-122018, MK0653H-PHL-2019-019773
ORGANON (PHILIPPINES) INCORPORATED
23/F Menarco Tower 32nd St. Bonifacio Global City, Taguig City 1634
Tel & Fax: +632-84244260 | PH-ROS-110029 OCT/2022
•Rosuvastatin/ Ezetimibe fixed-dose combination provided significantly greater reduction in LDL-C level by 59%-63%1
Selected safety information (SSI)2: Contraindications: Hypersensitivity. Patients w/ active liver disease.
Pregnancy & lactation. Women of child-bearing potential not using appropriate contraceptive measures. Precautions: Discontinue therapy if CK levels are markedly elevated (>10 x ULN) or if myopathy is diagnosed or suspected. Patients w/ predisposing factors for myopathy. Temporarily w/ held therapy in patients w/ an acute serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis. Concomitant use w/ ciclosporin, fibric acid derivatives (including gemfibrozil), nicotinic acid, azole antifungals & macrolides; daptomycin; gemfibrozil; fenofibrate & other fibrates; anticoagulant. Diabetes mellitus. Patients who consume excessive quantities of alcohol &/or have a history of liver disease. Not recommended in patients w/ moderate or severe hepatic impairment. Asians. Adverse events: Common: Pruritus
References:
1. Kim KJ, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovas Ther. 2016 Oct;34(5):371-82.
2. Full product information of Rosuzet: S-CDDS-MK0653H-T-122018, MK0653H-PHL-2019-019773
ORGANON (PHILIPPINES) INCORPORATED
23/F Menarco Tower 32nd St. Bonifacio Global City, Taguig City 1634
Tel & Fax: +632-84244260 | PH-ROS-110029 OCT/2022
